Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request

This article was originally published in The Gray Sheet

Executive Summary

The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson

You may also be interested in...



Drug-eluting stent litigation

Wilmington, Del. federal court schedules June 2005 hearing of patent infringement suits exchanged between Boston Scientific and Johnson & Johnson. Judge Sue Robinson rejected requests for injunctions against sales by both firms last November; however, she noted J&J has a "likelihood of success on the merits" of the case (1"The Gray Sheet" Dec. 1, 2003, p. 17)...

Drug-eluting stent litigation

Wilmington, Del. federal court schedules June 2005 hearing of patent infringement suits exchanged between Boston Scientific and Johnson & Johnson. Judge Sue Robinson rejected requests for injunctions against sales by both firms last November; however, she noted J&J has a "likelihood of success on the merits" of the case (1"The Gray Sheet" Dec. 1, 2003, p. 17)...

Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit

Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel